Drugs / AK139
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07502222 | Apr 2026 → Nov 2027 expected | atopic eczema | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07436234 | Mar → Sep 2026 overdue | seasonal allergic rhinitis | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07436221 | Feb → Dec 2026 expected | asthma | Akeso | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-11 | Akeso | Regulatory 康方生物IL-4Rα/ST2双抗获批开展7项呼吸及自免疾病II期临床 akesobio.com ↗
近日，国家药品监督管理局批准了康方生物（9926.HK）自主研发的全球首个靶向IL-4Rα/ST2双特异性抗体AK139共7项适应症II期临床的开展，包括慢性阻塞性肺疾病、重度支气管哮喘、慢性自发性荨麻疹、过敏性鼻炎、慢性鼻窦炎伴鼻息肉、中重度特应性皮炎、结节性痒疹. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-11 | Akeso | 康方生物IL-4Rα/ST2双抗获批开展7项呼吸及自免疾病II期临床 akesobio.com ↗ |
| 2025-02-14 | Akeso | 非肿瘤首个双抗|康方生物全球首创IL-4Rα/ST2（AK139）IND获受理，剑指呼吸系统及皮肤疾病领域 akesobio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK139 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07502222 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT07436221 ↗ |